Specific niche view of the structured sector hierarchy. Useful for precedent work where broader sector slices include too much noise.
| Target | Buyer / Investor | Sector | Geo | Transaction size | EV / EBITDA |
|---|---|---|---|---|---|
| Nordic Group bv | Alfasigma spa | Proprietary & Advanced Pharmaceuticals | $431M – $583M | 10× – 14× | |
| Recordati | Respighi BidCo spa, CVC Capital Partners Fund IX, Groupe Bruxelles Lambert (GBL), Abu Dhabi Investment Authority (ADIA), CPP Investments, MGG Strategic SICAF SIF, CapSol, PSP Investments, StepStone, AlpInvest, Andrea Recordati | Proprietary & Advanced Pharmaceuticals | $11,612M | 13.8× | |
| BioXcel Therapeutics Inc. | Teva Pharmaceuticals International GmbH | Proprietary & Advanced Pharmaceuticals | $4.2M – $5.8M | 3× – 3× | |
| Biohaven | SK Biopharmaceuticals | Proprietary & Advanced Pharmaceuticals | $350M | n/m | |
| Alesta Therapeutics | BioMarin Pharmaceutical | Proprietary & Advanced Pharmaceuticals | $275M | n/m | |
| Soleno Therapeutics Inc. | Neurocrine Biosciences Inc. | Proprietary & Advanced Pharmaceuticals | $2,900M | n/m | |
| Emalex Biosciences | Teva Pharmaceutical Industries | Proprietary & Advanced Pharmaceuticals | $700M | n/m | |
| Redx Pharma | Skye Bioscience | Proprietary & Advanced Pharmaceuticals | $125M | n/m | |
| AGB-Pharma | Atlas Health Capital | Proprietary & Advanced Pharmaceuticals | $45.0M – $60.9M | n/m | |
| Assertio | Zydus Life | Proprietary & Advanced Pharmaceuticals | $166M | 7× – 9× |
Bins are observed deal frequencies across disclosed transactions. Use as a directional reference, not a target valuation.
Use the directory on the recent deals hub to switch between countries, sectors and sub-sectors. A free account unlocks the structured filters that go beyond the public view.